Plasminogen Activator Inhibitor-1 and Transforming Growth Factor β2 in the Aqueous Humour of Patients with and without Glaucoma | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 8, Volume 27, Issue 2, December 2007, Page 105-114 PDF (178.45 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/besps.2007.37308 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mona Abdel Hamid* 1; Iman Fahmy2; Ahmed Helal2 | ||||
| 1Medical Biochemistry Department, Research Institute of Ophthalmology | ||||
| 2Ophthalmology Department, Research Institute of Ophthalmology | ||||
| Abstract | ||||
| This study was performed to determine the levels of plasminogen activator inhibitor-1 (PAI-1), transforming growth factor ß2 (TGFß2) and total protein in the aqueous humour of patients with glaucoma versus those without glaucoma. A total of 30 aqueous humour samples were collected from patients with glaucoma and cataract (20 glaucoma aqueous samples and 10 cataractaqueous samples). The levels of PAI-1 and TGFß2 were determined by enzyme linked immunosorbent assay (ELISA), while total protein levels by the Bradford method. There was a significant increase in the aqueous levels of PAI-1, TGFB2 and total protein in the glaucoma group compared to the cataract group. Further analysis of the glaucoma group showed a significant increase in the levels of PAI-1, TGFß2 in patients with late compared to patients with early open angle glaucoma. There was a significant positive correlation between the levels of PAI-1 and total protein in patients with glaucoma. Also a significant positive correlation was detected between PAI-1 and TGFß2 in both glaucoma groups. These data are consistent with the possibility that intraocularly produced PAI-1 may contribute to glaucoma pathogenesis. So, reducing the production or activity of PAI-1 in the eye could constitute a new targetfor the design of glaucoma therapy. | ||||
|
Statistics Article View: 96 PDF Download: 150 |
||||
